Filing summary
Entity discrepancy: The request identifies Nexttrip, Inc., but the supplied Form 10-Q is for Sigma Labs, Inc. This summary reflects the filing text and does not establish that it belongs to Nexttrip.
Business context and reporting period
This unaudited 10-Q covers the quarter and nine months ended September 30, 2015; it was signed November 10, 2015. Sigma Labs develops manufacturing and materials technologies, focusing on its PrintRite3D quality-assurance software, engineering consulting, and metal additive-manufacturing services. Revenue remained primarily from consulting, with limited technology licensing.
Financial performance and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $266,566 | $92,449 | $648,515 | $322,091 |
| Gross profit | $241,316 | $56,123 | $510,136 | $145,137 |
| Gross margin | 90.5% | 60.7% | 78.7% | 45.1% |
| Net loss | $(587,130) | $(539,438) | $(1,399,378) | $(2,802,253) |
| Cash used in operations | Not stated for quarter | Not stated for quarter | $(1,038,885) | $(729,068) |
At September 30, cash was $1.84 million, versus $2.96 million at December 31, 2014. Working capital was $1.99 million, down from $2.81 million. Total liabilities were $206,259, all current; the filing reports no credit facilities and no interest expense. Total assets were $3.14 million and stockholders’ equity was $2.93 million. The company reported no income-tax expense. Basic and diluted loss per share was reported as $(0.00) for all periods shown.
Changes versus comparable periods
- Revenue rose approximately 188% in Q3 and 101% for the first nine months, primarily due to additional contracts. Management attributed the nine-month revenue chiefly to engineering consulting.
- Gross margin improved in both comparisons, while operating costs remained substantial. Q3 net loss widened by about $48,000; nine-month net loss narrowed by about $1.40 million, largely because 2014 included a nonrecurring $1.28 million warrant-extension expense.
- Nine-month operating cash use increased by about $310,000 year over year. Cash declined by $1.13 million during the first nine months of 2015; there were no financing cash proceeds in that period, compared with $3.68 million of net financing cash in 2014.
- Research and development expense increased to $206,545 from $147,683 for nine months. General and administrative expense rose to $886,965 from $564,581; management cited greater investor-relations and consulting activity. Payroll expense declined to $338,533 from $387,564, partly because the prior-year period included a $175,000 executive bonus.
Outlook, risks, and unusual items
- Management said available funds and expected receipts were sufficient for administrative and operating expenses through 2016, based on consulting work, PrintRite3D sales or licenses, and securities offerings. This is conditional: the company had no committed external capital and said additional securities or borrowing would likely be needed. It warned that failure to obtain funding could force delays, reductions, or cancellation of commercialization efforts.
- As of November 10, management expected up to approximately $220,000 of revenue from three active consulting contracts for the remainder of 2015, subject to performance milestones. A delay in work under a GE Aviation-led contract shifted some expected revenue into 2016. Fixed-price contracts also expose the company to cost-estimation and delivery risks.
- PrintRite3D CONTOUR was launched for beta installations; the first field application was delivered to Honeywell Aerospace in October 2015. The company also launched an OEM Partner Program and Early Adopter Program; it reported one Early Adopter customer as of the filing date. These developments had not yet established significant product revenue.
- The company formed a 50%-owned joint venture with Arete Innovative Solutions for additive-manufacturing opportunities. Sigma accounted for its interest using the equity method and recorded a $108 loss for the quarter.
- At September 30, 2.5 million warrants remained outstanding at an $0.08 exercise price, expiring in January and June 2016. Warrants covering 16.3 million shares at $0.15 expired during the first nine months. Equity compensation and stock-based grants remained significant; common shares outstanding were reported as 620.2 million at September 30, with 623.6 million issued.
- The filing says disclosure controls were effective at a reasonable-assurance level and reports no material quarterly change in internal control over financial reporting. Legal proceedings and separate risk-factor disclosures were marked “not applicable” in this 10-Q; the filing refers readers to the 2014 Form 10-K for risk factors. No subsequent events requiring disclosure were identified.
Important facts for investors to verify
- Confirm whether this Sigma Labs filing is the intended document, given the Nexttrip, Inc. request metadata.
- Check the cover-page share count: it states 623,594,835 shares issued and outstanding as of November 10, while the September 30 financial statements distinguish 623,594,835 issued from 620,219,835 outstanding.
- Assess the assumptions behind management’s stated funding runway through 2016, including contract milestones, product commercialization, and potential financing; no financing commitment was disclosed.
- Track conversion of beta programs, licenses, and announced partnerships into recurring product revenue, and monitor consulting-contract timing and fixed-price cost exposure.
- Review the 2014 Form 10-K risk factors and subsequent filings for developments not detailed in this quarterly report.